Four lots of Lisinopril dosed at 5 mg are affected by this recall due to a defect in printing on the plates “which can induce a risk of overdose”. Other generics, such as Biogaran, Teva, Zentiva, Sandoz or Arrow offer this molecule.
More than 32,000 boxes of a generic drug against hypertension and heart failure, Lisinopril, were recalled in France due to a “printing” on platelets “which could induce a risk of overdose”, said the National Agency for Medicines (ANSM) on Tuesday, May 6, 2025.
The quality of the tablets marketed by the American laboratory Viatris “is not called into question” but “the registration present on the aluminum of the brochure can lend to confusion because it suggests that it is necessary to take several tablets certain days”, specifies the ANSM in a press release.
What are the Lisinopril lots concerned by the recall?
In total, four Lisinopril lots dosed at 5 mg are affected (lots 8172295, 8189879, 8172296, 8192737), or 32,640 boxes, according to a count obtained from the ANSM.
-In the event of overdose, it is possible to feel fatigue, balance disorders, hypotension and “alteration of kidney function may occur”, warns the drug’s guardian.
A case of overdose accompanied by an unworthy confusing state has been reported, according to the ANSM.
“Alternatives are available”
Until new lots with compliant plates are “available soon”, no supply voltage in Lisinopril is planned following this recall, according to the agency, because “alternatives are available”.
Other genericers, such as Biogaran, Teva, Zentiva, Sandoz or Arrow offer this molecule, according to the Vidal Data Database in France.
